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Abstract: Stroke is a major cause of mortality and disability worldwide. The main cause of 
stroke is atherosclerosis, and the most common risk factor for atherosclerosis is hypertension. 
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Therefore, antihypertensive treatments are recommended for the prevention of stroke. Three 
angiotensin receptor blockers (ARBs), telmisartan, irbesartan and candesartan, inhibit the 
expression of the receptor for advanced glycation end-products (RAGE), which is one of the 
pleiotropic effects of these drugs. High mobility group box 1 (HMGB1) is the ligand of 
RAGE, and has been recently identified as a lethal mediator of severe sepsis. HMGB1 is an 
intracellular protein, which acts as an inflammatory cytokine when released into the 
extracellular milieu. Extracellular HMGB1 causes multiple organ failure and contributes to 
the pathogenesis of hypertension, hyperlipidemia, diabetes mellitus, atherosclerosis, 
thrombosis, and stroke. This is the first review of the literature evaluating the potential of 
three ARBs for the HMGB1-RAGE axis on stroke therapy, including prevention and acute 
treatment. This review covers clinical and experimental studies conducted between 1976 and 
2013. We propose that ARBs, which inhibit the HMGB1/RAGE axis, may offer a novel 
option for prevention and acute treatment of stroke. However, additional clinical studies are 
necessary to verify the efficacy of ARBs. 
Keywords: stroke; telmisartan; irbesartan; candesartan; high mobility group box 1;   
receptor for advanced glycation end-products 
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VCAM-1, vascular cell adhesion molecule-1; VEGF, vascular endothelial growth factor; VSMCs, 
vascular smooth muscle cells. 
1. Introduction 
Stroke was the second most common cause of death worldwide in 2011, resulting in 6.2 million 
deaths (11.4% of the total) in statistics of the World Health Organization. Stroke is also the second 
leading cause of death and the leading cause of adult disability in the USA, with an estimated cost of 
$68.9 billion annually [1,2]. The overall costs of stroke care will account for 6.2% of the total burden of 
illness by 2020 [2]. The major cause of stroke is atherosclerosis. Three of the most common risk  
factors for atherosclerosis are hypertension (HT), hyperlipidemia (HL), and diabetes mellitus (DM) [3]. 
Antihypertensive treatment is recommended for the prevention of stroke because HT is the single most 
important modifiable risk factor for stroke [4]. 
Telmisartan, irbesartan, and candesartan are angiotensin receptor blockers (ARBs), which are widely 
used to treat patients with HT. These ARBs inhibit the expression of the receptor for advanced glycation 
end-products (RAGE), which is induced by an inflammatory factor, tumor necrosis factor-α (TNF-α), in 
human endothelial cells [5]. Grossin et al. reported that modulating RAGE expression by correcting 
endothelial dysfunction is achievable by drugs already used for HT or DM treatment, such as ARBs [5]. 
Therefore, these ARBs may be useful in the prevention of stroke. 
2. Advanced Glycation End-Products (AGEs) and RAGE 
AGEs are modifications of proteins or lipids that become nonenzymatically glycated and oxidized 
after contact with sugars. Sporadically elevated levels of blood glucose induce the generation of largely 
irreversible AGEs, which accumulate in tissues and plasma of humans and rodents with normal aging, 
and their rate of accumulation is greatly increased in DM [6–8]. 
RAGE is a central cell-surface receptor for AGEs, and is also a multi-ligand receptor, which  
is a member of the immunoglobulin superfamily of cell-surface molecules [9,10]. RAGE acts as  
the counter-receptor of integrin, an endothelial adhesion receptor, in leukocytes, and activation of  
RAGE reduces leukocyte recruitment. Therefore, RAGE propagates cellular dysfunction in several 
inflammatory disorders [11]. 
Although the activation of RAGE mediated by its ligands evokes inflammatory cell infiltration and 
activation of the vessel wall, soluble RAGE (sRAGE), the truncated form spanning the extracellular 
binding domain of RAGE, shows potent anti-inflammatory effects produced by the action of absorbents 
for AGEs [12]. Soluble RAGE, which potentially counteracts AGEs, consists of several forms, including 
endogenous secretory RAGE (esRAGE; a splice variant of RAGE) and cleaved-type sRAGE, which is 
derived from cell-surface RAGE [13]. A review by Schmidt et al. demonstrated that the binding of 
AGEs to RAGE is a critical step in a mechanism for chronic vascular dysfunction in diabetic 
vasculopathy and atherosclerosis [14]. 
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3. High Mobility Group Box 1 (HMGB1) 
HMGB1, a predominantly nuclear protein, is expressed in many eukaryotic cells with a highly 
conserved sequence among species [15]. HMGB1 acts as an intracellular regulator of transcription, such 
as p53 and nuclear factor-κB (NF-κB), and plays a crucial role in the maintenance of DNA  
functions [16]. RAGE is able to bind some ligands (e.g., HMGB1 and AGEs) and is implicated in  
many HMGB1 effects [17]. HMGB1 is released from various cells (e.g., macrophages/monocytes, 
endothelial cells, and pituicytes) when these cells are stimulated by lipopolysaccharide or TNF-α. 
HMGB1 acts as a proinflammatory cytokine through RAGE and toll-like receptors 2 and 4, and it  
is also released from necrotic cells [18–24]. HMGB1 is a member of the “alarmin” family, a group of 
endogenous factors that act from the extracellular space after release, and also activate the inflammatory 
response through the binding of membrane receptors [25,26]. HMGB1 has been identified as a lethal 
mediator of severe sepsis. HMGB1 levels are markedly increased during severe sepsis in humans and 
mice. Administration of neutralizing antibodies that are specific for HMGB1 reduces the lethality of 
mice with sepsis [23]. In addition, HMGB1 contributes to the pathogenesis of disorders in various 
organs, such as the heart, liver, lungs, gut, pancreas, joints, spine, and periodontium, and is implicated in 
graft rejection in transplantation [22,23,27–38]. Furthermore, inactivation of HMGB1 using an 
anti-HMGB1 monoclonal antibody (McAb) or short hairpin RNA-mediated HMGB1 has already been 
shown to be effective in various animal models of cancer, rheumatoid arthritis, myocardial infarction, 
hepatic ischemia, acute pancreatitis, hemorrhagic shock, and sepsis [23,39–44]. 
However, anti-HMGB1 and short hairpin RNA-mediated HMGB1 are not currently used clinically. 
Therefore, clinically approved drugs, such as telmisartan, irbesartan, and candesartan, which inhibit the 
HMGB1/RAGE axis, may be useful in the prevention and treatment of various diseases. 
4. Experimental Studies of ARBs 
In vitro studies using neuron–astrocyte co-cultures have demonstrated protective effects of 
telmisartan on ischemic neuronal injury [45]. Oxygen-glucose deprivation (OGD) is widely used as  
an in vitro ischemic model [46]. Telmisartan attenuates OGD-induced cellular damage, and suppresses 
OGD-induced extracellular release of glutamate, production of reactive oxygen species (ROS), and 
generation of nitric oxide (NO) [45]. 
In vivo studies have demonstrated protective effects of telmisartan, irbesartan, and candesartan on 
neuronal injury. Stroke-prone spontaneously hypertensive rats (SHRSPs), which developed from 
normotensive Wistar Kyoto rats, have proven useful for the study of the pathogenesis of stroke and for 
the testing of prophylactic anti-stroke compounds [47,48]. SHRSPs develop severe hypertension with 
age and die from ischemic stroke or hemorrhagic stroke in greater than 80% of the animals [47]. 
Telmisartan reduces the incidence of stroke, prolongs survival, and improves neurological outcome in 
SHRSPs [49]. Irbesartan also increases the survival rate in SHRSPs fed a high-salt and low-protein diet, 
and ameliorates the appearance of stroke symptoms, showing an association with the prevention of 
microscopic lesions [50]. Candesartan reduces the incidence of stroke in SHRSPs [51]. These findings 
demonstrate that telmisartan, irbesartan, and candesartan prevent stroke in SHRSPs. Int. J. Mol. Sci. 2013, 14  18903 
 
Middle cerebral artery occlusion (MCAO) is widely used as an animal model of ischemic stroke. 
Tyrosine-related kinase B (TrkB) is the receptor of brain-derived neurotrophic factor (BDNF) [52]. 
BDNF acts on certain neurons of the central and peripheral nervous systems to support the survival of 
existing neurons, and encourage the growth and differentiation of new neurons and synapses [53,54]. 
Telmisartan improves neurological outcome, reduces infarct size and TNF-α levels, and induces 
expression of the TrkB receptor and neuronal survival in a rat MCAO model [49]. Irbesartan also 
improves neurological outcome, reduces infarct size, decreases the number of apoptotic cells in  
the peri-infarct cortex, and attenuates the invasion of activated microglia and macrophages in the 
peri-infarct cortex in the rat MCAO model [55]. Furthermore, irbesartan decreases TNF-α levels, and 
inhibits the monocyte chemoattractant protein-1 (MCP-1)/C-C chemokine receptor 2 (CCR2) signaling 
pathway in the rat MCAO model [56]. Candesartan reduces infarct size, improves neurological outcome, 
increases cerebral blood flow, and stimulates the neurotrophin BNDF/TrkB system in the rat MCAO 
model [57,58]. Inhibition of metalloproteinase (MMP)-2 and MMP-9 reduces neuronal and glial 
apoptosis [59]. Furthermore, Guan et al. reported that MMP-2, MMP-9, and vascular endothelial growth 
factor (VEGF) are significantly increased by MCAO, but candesartan fails to reduce MMP-2, MMP-9, 
and VEGF in the rat MCAO model [60]. These findings show that telmisartan, irbesartan, and 
candesartan reduce infarct size and improve neurological outcome in ischemic stroke model rats. 
Many experimental studies on stroke model animals have demonstrated that telmisartan, irbesartan, 
and candesartan have protective effects on the structure of neurons and vessels (Table 1), and fulfill 
many Stroke Therapy Academic Industry Roundtable (STAIR) criteria [61]. However, data from in vivo 
and in vitro studies indicate that it is not clear whether inhibition of the HMGB1/RAGE axis directly 
contributes to the prevention and treatment of stroke. 
Table 1. Stroke Therapy Academic Industry Roundtable (STAIR) quality of telmisartan, 
irbesartan, and candesartan. 
Item Description  Telmisartan  Irbesartan  Candesartan 
Laboratory setting  Focal model tested in two or more laboratories  √  √  √ 
Animal species  Focal model tested in two or more species  √  √  √ 
Health of animals  Focal model tested in old or diseased animals   
(e.g., diabetic, hypertensive, aged, and hyperglycemic) 
√  √  √ 
Sex of animals  Focal model tested in male and female animals  ×  ×  × 
Reperfusion  Tested in temporary and permanent   
models of focal ischemia 
√  √  √ 
Time window  Drug administered at least 1 h   
after occlusion in focal model 
× × √ 
Dose response  Drug administered using   
at least two doses in focal model 
√  √  √ 
Route of delivery  Tested using a feasible mode of delivery   
(e.g., not intracisternal or intraventricular,   
cortical transplant or graft only) 
× × × 
Endpoint  Behavioral and histological outcomes measured  √  √  √ 
Long-term effect  Outcome measured at 4 or more weeks after occlusion 
in focal models 
√ × × 
Total   7  6  7 
The number of STAIR criteria met by the drug (maximum: 10) are listed. Int. J. Mol. Sci. 2013, 14  18904 
 
5. Clinical Studies of ARBs 
The three ARBs, telmisartan, irbesartan, and candesartan, were effective in several double-blind 
clinical studies for stroke (Table 2). These ARBs were administered by various methods, such as  
oral, intravenous, interacisternal or intraperitoneal in animal studies, whereas, these ARBs were 
administered by oral in clinical studies. Therefore, some factors, such as BBB permeability of the drug, 
concentration of the drug in the certain brain tissue and drug metabolism may contribute to the discrepancy 
between animal studies and clinical studies with regards to prevention and treatment outcomes. 
Table 2. Major clinical studies of telmisartan, irbesartan, and candesartan in stroke. 
Drugs  Effect for stroke  Sample size  p value  Study name  Reference 
Telmisartan 
Prevention 20,332  0.23  PRoFESS  [62] 
Prevention 25,611  –  ONTARGET  [63] 
Prevention 5926  0.136  TRANSCEND  [64] 
Irbesartan 
Prevention 9016  0.20  ACTIVE  I  [65] 
Acute treatment  43  0.066  –  [66] 
Candesartan 
Prevention 4964  0.06  SCOPE  [67] 
Prevention 4728  0.198  CASE-J  [68] 
Prevention 2048  –  E-COST  [69] 
Prevention, acute treatment  2029  0.38, 0.47  SCAST  [70] 
5.1. Telmisartan 
The results of three recent clinical studies of telmisartan, including the Prevention Regimen For 
Effectively avoiding Second Strokes (PRoFESS) [62], Ongoing Telmisartan Alone and in Combination 
with Ramipril Global Endpoint Trial (ONTARGET) [63], and the Telmisartan Randomized Assessment 
Study in ACE-intolerant Subjects with Cardiovascular Disease (TRANSCEND) [64] have suggested  
a modest neurovascular protective effect of telmisartan against stroke events. The PRoFESS study 
compared placebo with telmisartan in 20,332 patients who recently had an ischemic stroke [62]. Therapy 
with telmisartan (80 mg per day) initiated soon after an ischemic stroke (the median interval was  
15 days) and continued for 2.5 years, did not significantly lower the rate of recurrent stroke, but there 
was a trend for the reduction of recurrent stroke (p = 0.23). The PRoFESS study group suggested that the 
duration of the study may have been too short, which may have contributed to a lack of significant 
benefit associated with telmisartan. The ONTARGET study compared an angiotensin-converting 
enzyme (ACE) inhibitor, ramipril (10 mg per day), telmisartan (80 mg per day), and a combination of 
both drugs in 25,611 patients with vascular disease or high-risk DM over a median follow-up period of 
56 months [63]. Ramipril, telmisartan, and combination therapy proved to be equivalent with regard to 
the prevalence of recurrent stroke. Furthermore, the TRANSCEND study compared placebo with 
telmisartan (80 mg per day) in 5926 patients intolerant to ACE inhibitors over a median follow-up period 
of 56 months. The TRANSCEND study found that the incidence of stroke was reduced by 17% in the 
telmisartan group, but significant differences were not noted (p = 0.136) [64]. Incidentally, these  
studies on telmisartan such as PRoFESS, ONTARGET, and TRANSCEND, were supported by 
Boehringer Ingelheim. Int. J. Mol. Sci. 2013, 14  18905 
 
5.2. Irbesartan 
Clinical studies on prevention and acute treatment of stroke have been performed for irbesartan.  
The Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE I) 
study compared placebo with irbesartan once daily (at a dose of 150 mg per day for 2 weeks, and  
300 mg per day thereafter) in 9016 patients with atrial fibrillation over a median follow-up period of  
4.1 years [65]. Irbesartan significantly reduced the incidence of stroke, transient ischemic attack, and 
non-central nervous system embolism compared with placebo in this study (p = 0.02). However, 
irbesartan did not show the significant reduction in incidence of stroke compared with placebo in this 
study (p = 0.20). This ACTIVE I study was supported by Pfizer. 
Furthermore, irbesartan (150 mg per day) was compared with placebo in 43 patients in a clinical 
study of early treatment of acute ischemic stroke [66]. There were no significant differences between 
these two groups in neurological outcome (National Institutes of Health Stroke Scale [NIHSS] score) 
after 30 days (p = 0.066). The sample size in this study may have been too small, which may have 
contributed to the lack of significant benefit associated with irbesartan. This study was supported by 
Bristol-Myers Squibb and Sanofi-Aventis. 
5.3. Candesartan 
Clinical studies of prevention and treatment of stroke have also been performed for candesartan.  
The efficacy of candesartan in preventing stroke was tested in the Study on Cognition and Prognosis  
in the Elderly (SCOPE). The SCOPE study compared placebo with candesartan (8–16 mg per day) in  
4964 patients [67]. There were significant reductions in nonfatal stroke (p = 0.04) and a trend for a 
reduction in all types of stroke (p = 0.06) in the candesartan group. Incidentally, this SCOPE study  
was supported by AstraZeneca. Although candesartan also prevented stroke in two clinical studies, 
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) [68] and Efficacy of Candesartan 
on Outcome in Saitama Trial (E-COST) [69], these studies were not double-blind tests. Furthermore, the 
efficacy of candesartan for preventing stroke and improving neurological outcome (Barthel index) was 
tested in the Scandinavian Candesartan Acute Stroke Trial (SCAST). The SCAST study compared 
placebo with candesartan (doses increasing from 4 mg on day 1 to 16 mg on days 3 to 7) in 2029 patients 
with acute stroke (ischemic or hemorrhagic) [70]. There were no significant differences among both groups 
in the incidence of stroke (p = 0.38) and neurological outcome (p = 0.47) after six months. However, in 
patients within 6 h of symptom onset, there was a trend in preventing the incidence of stroke and improving 
clinical outcome in the candesartan group (p = 0.08). This SCAST study was supported by AstraZeneca. 
Recently, the comparative effectiveness of ARBs for preventing stroke, heart failure, or acute 
myocardial infarction, such as telmisartan, irbesartan, candesartan, losartan, or valsartan, was investigated 
in 54,186 patients with DM in a population-based randomized cohort study [71]. The study results 
suggested that telmisartan and valsartan are associated with a lower risk of admission to hospital for 
stroke, heart failure, or acute myocardial infarction in older patients with DM [71]. Currently, comparing 
the efficiency in reduction of the incidence of stroke events and improvement in neurological outcome 
may not be possible for these ARBs in randomized, controlled clinical studies. However, in major 
clinical studies, the application of ARBs shows a trend towards the reduction of recurrent stroke. Int. J. Mol. Sci. 2013, 14  18906 
 
6. HMGB1/RAGE and Risk Factors of Stroke 
HMGB1 acts as a proinflammatory cytokine, and may play a role in the progression of risk factors  
of stroke, such as HT, HL, DM, atherosclerosis, and thrombosis. Inhibition of the HMGB1/RAGE  
axis may be an effective treatment for these risk factors of stroke. 
6.1. Hypertension 
HMGB1 and RAGE contribute to the pathogenesis of HT. A hypertensive challenge has an early  
and sustained effect on RAGE upregulation in brain vessels of the cortex and hippocampus in mice [72]. 
Plasma sRAGE levels are decreased in patients with essential HT [73]. Nakamura et al. reported  
that in patients with essential HT, plasma sRAGE levels are associated with body mass index,  
waist circumference, and alanine aminotransferase, gamma-glutamyltranspeptidase, 24-hour creatinine 
clearance, B-type natriuretic peptide, and TNF-α levels [74]. Telmisartan decreases serum sRAGE levels 
in patients with essential HT [75]. In addition, Nakamura et al. reported that telmisartan significantly 
reduced serum HMGB1 levels compared with enalapril (ACE inhibitor) in autosomal dominant 
polycystic kidney disease patients with HT [76]. These findings show that RAGE may contribute to the 
pathogenesis of HT. It is possible that the hypertensive challenge may upregulate RAGE in brain vessels 
in human, and that telmisartan may inhibit serum HMGB1 levels in patients with HT. However, it is still 
unclear whether telmisartan inhibits upregulation of RAGE in patients with HT, and whether it inhibits 
relative activation of RAGE in patients with HT. Because telmisartan decreases serum sRAGE and 
HMGB1 levels in patients with HT, either inhibition or augmentation of the HMGB1/RAGE axis could 
occur in patients with HT. 
6.2. Hyperlipidemia 
HMGB1 and RAGE also contribute to the pathogenesis of HL. Cell culture experiments using 
monocyte cell culture (U937) have demonstrated relocation of HMGB1 from the nucleus to the 
cytoplasm under hyperlipidemic stress [77]. A high level of HMGB1 in serum and the cytosol of lung 
epithelial cells are positively correlated with the upregulation of RAGE in lung tissue from 
hyperlipidemic golden Syrian hamsters [77]. Santilli et al. reported that sRAGE in plasma was 
significantly lower in hypercholesterolemic patients than in normocholesterolemic patients [78]. 
Therefore, some experimental and clinical studies have demonstrated that HMGB1 and RAGE may 
contribute to the pathogenesis of HL. In human, it is possible that the hyperlipidemic stress may increase 
in HMGB1 level in serum and upregulate RAGE in tissue. At least, RAGE may be upregulated as  
a result of HT and HL, rather than being the cause of HT and HL. 
6.3. Diabetes Mellitus 
HMGB1 and RAGE are thought to play a role in the progression of DM [79]. Hyperglycemia 
increases the expression of HMGB1 and RAGE in human aortic endothelial cells [80]. Moreover, earlier 
and enhanced accumulation of AGEs in DM has been linked to the pathogenesis of vascular and 
inflammatory cell complications that typify DM [6–8]. Ichikawa et al. reported that AGEs induce 
expression of tissue factor in human monocyte-like U937 cells and in monocytes from diabetic patients, Int. J. Mol. Sci. 2013, 14  18907 
 
and that AGEs may promote thrombosis and the development of atherosclerosis by inducing expression 
of tissue factor in monocytes in patients with DM [81]. Furthermore, in vitro experiments have shown 
that RAGE binding to AGEs leads to changes in endothelial cells and pericytes, which are similar to the 
characteristics known as diabetic microangiopathy [82]. Activation of RAGE induces elevation in 
generation of superoxide by mononuclear phagocytes in patients with DM [83]. These in vitro studies 
have demonstrated that AGEs and RAGE may contribute to the pathogenesis of diabetic 
microangiopathy in DM. 
When the expression of RAGE has been interrupted by using small interfering RNA (siRNA) in 
diabetic human monocytes, a reduction in RAGE significantly inhibits the expression of CD36 and the 
production of ROS [84]. This suggests a positive interaction between the expression of RAGE and the 
expression of CD36 and generation of ROS in monocytes. Vascular smooth muscle cells (VSMCs) 
derived from insulin-resistant and diabetic db/db mice display an increased expression of RAGE and 
migration capability compared with VSMCs derived from control db/+ mice. The application of RAGE 
antibodies interferes with enhanced migration capability in db/db cells [85]. Based on these results, 
inhibition of RAGE may reduce oxidative stress and migration of VSMCs in DM. 
RAGE is expressed in many cell types, including endothelial cells, monocytes, smooth muscle cells, 
and fibroblasts, at low levels in healthy adult animals, but at significantly higher levels in DM [86–88]. 
Lewis et al. reported an increase in expression of RAGE, vascular cell adhesion molecule-1 (VCAM-1), 
VEGF, and connective tissue growth factor in diabetic ApoE(−/−) mice [89]. RAGE-induced   
cytosolic production of ROS facilitates the production of mitochondrial superoxide in hyperglycemic 
environments. A deficiency in RAGE prevents diabetes-induced increases in renal mitochondrial 
superoxide and renal cortical apoptosis in diabetic RAGE(−/−) mice [90]. These in vivo studies  
indicate that RAGE may contribute to an increase in oxidative stress and apoptosis in the DM model  
mouse kidney. 
Adipocyte hypertrophy induced by overexpression of RAGE is associated with suppression of 
glucose transporter type 4 and adiponectin mRNA expression, attenuated insulin-stimulated glucose 
uptake, and insulin-stimulated signaling [91]. RAGE (−/−) mice have significantly lower body weight, 
higher levels of adiponectin in serum, and higher sensitivity of insulin than wild-type mice. Furthermore, 
diabetic RAGE transgenic mice that overexpress RAGE in vascular cells exhibit exacerbation of 
nephropathy and retinopathy, and these are prevented by the inhibition of formation of AGEs [82]. In 
contrast to RAGE-overexpressing mice, diabetic RAGE knockout mice show marked improvement of 
nephropathy. These in vivo studies suggest that inhibition of RAGE may contribute to the pathogenesis 
of nephropathy and retinopathy in the DM model mouse. 
The anti-RAGE McAb, but not control Ab, prevents upregulation of transforming growth factor-β, 
development of submesothelial fibrosis, and fibronectin accumulation in the peritoneum of diabetic  
rats [92]. Candesartan significantly reduces expression of connective tissue growth factor and effectively 
suppresses the development of fibrotic deposition in diabetic rats [93]. Furthermore, candesartan 
reduces accumulation of AGEs and subsequent albuminuria by downregulating the nicotinamide 
adenine dinucleotide phosphate oxidase p47phox component and by inducing NO synthase expression, 
as well as by attenuating expression of RAGE in type 2 diabetic KK/Ta mouse kidneys [94]. These 
findings indicate that candesartan may have therapeutic effects in animal models of DM with a reduction 
in AGEs and RAGE. Int. J. Mol. Sci. 2013, 14  18908 
 
Many clinical studies have also demonstrated a relationship between DM and the HMGB1/RAGE 
axis. Levels of AGEs in serum and in plaques of patients with type 2 DM are higher than those  
in non-diabetics [95–97]. Cipollone et al. reported that overexpression of RAGE was associated with  
an enhanced inflammatory reaction and cyclooxygenase-2/microsomal prostaglandin E synthase-1 
expression in diabetic plaque macrophages [98]. This effect may contribute to plaque destabilization by 
inducing expression of MMP [98]. Despite an increase in expression of RAGE, expression of esRAGE 
is downregulated in the plaques of diabetic patients, and sRAGE and esRAGE levels in serum or plasma 
are also reduced compared with those in controls [99–103]. Univariate regression analysis showed that 
serum sRAGE levels are positively correlated with inflammatory markers, such as MCP-1 and TNF-α, 
in patients with type 2 DM [104]. In patients with diabetic microangiopathy, mean sRAGE levels in 
serum are significantly decreased compared with those in diabetic patients without microvascular 
complications [105]. Furthermore, the level of circulating esRAGE is significantly lower in type 1 
diabetic patients than in non-diabetic subjects, and is inversely associated with the severity of some 
diabetic vascular complications [106]. Circulating serum AGE and sRAGE levels are associated with 
the severity of nephropathy in type 2 DM patients [107]. Niu et al. reported convincing evidence 
regarding the association of the RAGE gene 1704T allele with an increase in risk of DM in a 
meta-analysis [108]. HMGB1 concentrations in serum are elevated in non-diabetic hyperglycemic 
patients and diabetic patients [109–111]. In a 12-year follow-up study, Nin et al. reported that higher 
plasma levels of HMGB1 were independently associated with a higher risk of all-cause mortality, and to 
a lesser extent, with a higher incidence of cardiovascular disease in patients with type 1 DM [112]. These 
clinical studies suggest that the HMGB1/RAGE axis may contribute to the pathogenesis of DM. 
Pharmacological intervention with AGEs, RAGE, and HMGB1 might provide a potential therapy  
for DM. 
6.4. Atherosclerosis 
HMGB1 and RAGE also contribute to the pathogenesis of atherosclerosis. Hu et al. reported that 
AGE-induced autophagy of VSMCs contributes to the process of AGE-induced proliferation of rat 
VSMCs, which is related to atherosclerosis in DM [113]. AGEs increase cell migration and proliferation 
in cultured rat VSMCs, and these effects interfere with anti-RAGE antibody [114]. Overexpression of 
RAGE induces MCP-1 expression in the rat VSMC line [115]. Telmisartan inhibits AGE-elicited cell 
injury by suppressing expression of RAGE via peroxisome proliferator-activated receptor-γ activation 
in human cultured microvascular endothelial cells [116]. Candesartan decreases TNFα induced RAGE 
expression at the mRNA and protein level along with a decrease in activity of NF-κB and expression of 
inflammatory mediators, such as VCAM-1 in human endothelial cells. [117]. In rat vascular adventitial 
fibroblasts, AGEs upregulate the expression of RAGE, and significantly increase the migration 
capability and the release of inflammatory mediators, such as MCP-1, interleukin-6, and   
VCAM-1 [118]. AGEs also upregulate NF-κB transcriptional activity and I kappaB alpha 
phosphorylation [118]. The application of candesartan, as well as anti-RAGE neutralizing antibody, 
significantly attenuates AGE-induced increase in RAGE, migration capability, and release of 
inflammatory mediators in rat vascular adventitial fibroblasts. These results suggest that telmisartan and 
candesartan may have anti-atherosclerotic effects. Int. J. Mol. Sci. 2013, 14  18909 
 
Wang et al. showed in cell and animal studies that N(ε)-carboxymethyl-lysine (CML), a major 
immunogen of AGE and the RAGE axis, may first initiate apoptosis of macrophages in atherosclerotic 
lesions and then induce the bone morphogenetic protein 2-core-binding factor α1-alkaline 
phosphatase-calcification cascade in a high-lipid, apoptosis-coexisting environment. CML is known as a 
major immunogen of AGE. Wang et al. showed that CML and RAGE were present in aortic lesions in 
diabetic apoE(−/−) mice [119]. Moreover, CML augments apoptosis of macrophages in a high-lipid 
environment in mice. CML also accelerates calcification of rat aortic VSMCs under high-lipid, 
apoptosis-coexisting conditions [119]. In response to carotid artery ligation in wild type mice, 
expression of RAGE is increased in the tissue of carotid arteries in a time-dependent manner. There is 
marked neointimal formation in the proximal area of ligation of carotid arteries in wild type mice, but 
this neointimal formation is attenuated in RAGE(−/−) mice [120]. Diabetic RAGE(−/−)/apoE(−/−) 
double knockout mice have significantly reduced atherosclerotic plaque areas compared with diabetic 
apoE(−/−) mice [121]. These effects on the vasculature produced by a reduction or absence of RAGE are 
associated with attenuation of leukocyte recruitment and decreased expression of proinflammatory 
mediators, including the NF-κB subunit RelA (p65), VCAM-1, and MCP-1. These effects on the 
vasculature are also associated with reduced oxidative stress because reduction of RAGE reduces 
expression of various nicotinamide adenine dinucleotide phosphate oxidase subunits, such as gp91phox, 
p47phox, and Rac1 [121]. Furthermore, atherosclerotic lesions and the average necrotic core area in the 
brachiocephalic arteries of old RAGE(−/−)/apoE(−/−) mice are significantly smaller than those in old 
RAGE(+/+)/apoE(−/−) mice [122]. Accumulation of HMGB1 is also significantly reduced in the 
atherosclerotic lesions of RAGE(−/−)/apoE(−/−) mice. These results indicate that reduction of RAGE 
inhibits expression of proinflammatory mediators and oxidative stress, and then attenuates changes in 
the vasculature with atherosclerosis. Therefore, it is possible that the HMGB1/RAGE axis contributes to 
the pathogenesis of atherosclerosis. 
Blockade of RAGE suppresses vascular hyperpermeability in rodent models of diabetic 
complications [123]. Furthermore, blockade of RAGE also suppresses atherosclerotic lesions in diabetic 
apoE(−/−) mice [123]. Blockade of RAGE also prevents neointimal formation in atherosclerotic lesions 
of hyperglycemic fatty Zucker rats subjected to balloon de-endothelialization injury of the carotid  
artery [123]. Similar to humans, atherosclerotic lesions express HMGB1 in diabetic apoE(−/−) mice that 
are fed a high-fat diet [124]. HMGB1 leads to macrophage migration, expression of proinflammatory 
mediators, and accumulation of immune and smooth muscle cells in diabetic apoE(−/−) mice [124]. 
However, treatment with anti-HMGB1 McAb attenuates atherosclerosis, macrophage accumulation in 
atherosclerotic lesions, and expression of VCAM-1, MCP-1, TNF-α, and interleukin-1β in diabetic 
apoE(−/−) mice [124]. Furthermore, treatment with candesartan or anti-HMGB1 McAb leads to 
antiatherosclerotic effects in diabetic apoE(−/−) mice [125]. Candesartan is more effective at reducing 
accumulation of macrophages and abundance of collagen I in atherosclerotic plaques than rosuvastatin 
(antilipid drug) in diabetic apoE(−/−) mice [125]. Therefore, these studies demonstrate that inhibition of 
HMGB1 or RAGE may attenuate changes in vasculature with atherosclerosis. 
In human atherosclerotic lesions, HMGB1 is expressed in endothelial cells, some intimal smooth 
muscle cells, and macrophages [126]. Inoue et al. reported that HMGB1 produced by the activation of 
VSMCs might contribute to the progression and vulnerability of human atherosclerotic lesions toward 
rupture [127]. Furthermore, Koyama et al. reported that the levels of esRAGE in human plasma are Int. J. Mol. Sci. 2013, 14  18910 
 
associated with components of atherosclerosis, and that esRAGE is a novel and potential protective 
factor for atherosclerosis [128]. Serum esRAGE levels are an independent risk factor for the progression 
of carotid atherosclerosis in type 1 DM [129]. Therefore, the HMGB1/RAGE axis may contribute to the 
pathogenesis of atherosclerosis, and inhibition of the HMGB1/RAGE axis may offer a novel option for 
treatment of atherosclerosis. 
Furthermore, HMGB1 contributes to the pathogenesis of thrombosis. Ito et al. reported that HMGB1 
inhibits the anticoagulant protein C pathway via the thrombin-thrombomodulin complex, and stimulates 
expression of tissue factor in monocytes in vitro, and that HMGB1 promotes development of 
microvascular thrombosis in rats [130]. It is possible that RAGE may be upregulated as a result of HT 
and HL, rather than being the cause of HT and HL in human. However, based on these findings, the 
HMGB1/RAGE axis could be a potential therapeutic target of risk factors of stroke, including HT, HL, 
DM, atherosclerosis, and thrombosis. 
7. HMGB1/RAGE in Acute Stroke 
In vitro and in vivo studies have clearly demonstrated the relationship between HMGB1/RAGE axis 
and acute stroke. In PC12 cells, levels of RAGE are increased after OGD culture [131]. Notably, 
blockade of RAGE with a selective RAGE antibody in vitro reduces the cytotoxicity caused by OGD. 
Oxygen deprivation triggers upregulation of the expression of the early growth response-1 gene and 
protein by activation of RAGE in murine aortic endothelial cells [132]. Rapid activation of the early 
growth response-1 gene and protein in hypoxia also upregulates fundamental inflammatory and 
prothrombotic stress genes. 
Kikuchi  et al. reported that HMGB1 is released into the extracellular space in the rat MCAO  
model and in PC12 cells exposed to OGD, and that HMGB1 induces apoptosis in PC12 cells [133,134]. 
Elevation of HMGB1 levels in the mouse brain induces memory abnormalities [135]. Moreover, 
Pedrazzi et al. reported that HMGB1 might inhibit glutamate uptake in adult mouse glia [136]. RAGE 
levels are elevated in the mouse brain after experimental stroke and systemic hypoxia, and increased 
expression of RAGE is mediated by hypoxia-inducible factor-1 in neurons after hypoxia or  
ischemia [137]. In MCAO rats, RAGE levels are high in the ischemic hemisphere relative to the 
non-ischemic hemisphere, and the expression of RAGE is primarily located in the penumbra of the 
ischemic hemisphere [131]. These results indicate that the release of HMGB1 and expression of RAGE 
in neurons may be increased in the stroke model. 
The number of surviving neurons in the hippocampal CA1 region is significantly higher in 
RAGE(−/−) mice than in wild-type mice after bilateral common carotid artery occlusion [138]. The size 
of MCAO-induced infarct areas in RAGE-knockout mice is small compared with that in wild-type 
mice [139]. Furthermore, activation of macrophages is decreased in RAGE-knockout mice [139]. 
RAGE might contribute to delayed neuronal death after global cerebral ischemia mediated by 
enhancement of vascular injury and deleterious glia-mediated inflammation. The reduction of RAGE 
may reduce the infarct area and inflammation in stroke model mice. 
Anti-HMGB1 McAb- or short hairpin RNA-mediated HMGB1 protects against brain injury by 
improving neurological outcome and infarction size in the rat MCAO model [140,141]. Furthermore, 
anti-HMGB1 McAb inhibits the development of brain edema through the protection of the blood–brain Int. J. Mol. Sci. 2013, 14  18911 
 
barrier and efficient clearance of circulating HMGB1 [142]. Treatment with telmisartan and 
anti-HMGB1 McAb- or short hairpin RNA-mediated HMGB1 has neurovascular protective   
effects [140–143]. Telmisartan inhibits expression of HMGB1 in macrophages/microglia via a 
peroxisome proliferator-activated receptor-γ-dependent mechanism in the mouse MCAO model [143]. 
These findings suggest that inhibition of HMGB1 may reduce the infarct area in stroke model animals. 
Furthermore, clinical and experimental studies have demonstrated a relationship between the 
HMGB1/RAGE axis and patients with acute stroke. HMGB1 is significantly elevated in the serum of 
patients with acute ischemic stroke compared with healthy volunteers [28]. Recently, Huanq et al. 
measured serum HMGB1 levels in 338 acute ischemic stroke patients, and reported that serum 
HMGB1 levels were an independent predictor of 1-year neurological outcome [144]. Similar results 
have been reported in patients with hemorrhagic stroke, as well as ischemic stroke. Compared with 
controls, patients with hemorrhagic stroke have markedly elevated serum HMGB1 levels, which are 
significantly correlated with IL-6 and TNF-α levels, and neurological outcome at 3 months [145]. Stroke 
patients express elevated RAGE levels in the ischemic hemisphere relative to the non-ischemic 
hemisphere [131]. Yokota et al. reported that low plasma sRAGE levels are associated with severe 
leukoaraiosis in acute stroke patients [146]. Moreover, Zimmerman et al. reported that AGEs might 
contribute to the severity of stroke patients with DM and other conditions characterized by AGE 
accumulation [147]. Therefore, these findings indicate that the HMGB1/RAGE axis may contribute to 
the pathogenesis of stroke. Neuronal cell death associated with cerebral ischemia is due to a lack of 
oxygen and glucose, and may involve the loss of ATP, excitotoxicity of glutamate, oxidative stress, 
reduction of neurotrophic support, and other metabolic stresses [148]. In addition to these factors, 
HMGB1 and RAGE may also contribute to exacerbation of cerebral ischemia. Therefore, the 
HMGB1/RAGE axis may provide a target for therapy in stroke. 
8. Conclusions 
Stroke is a frequent and severe neurovascular disorder. Therefore, prevention and treatment of stroke 
are crucial issues in humans. To prevent stroke, focus should be placed on reduction of risk factors, such 
as HT, HL, DM, atherosclerosis, and thrombosis. To reduce the risk of stroke, three ARBs, telmisartan, 
irbesartan, and candesartan, may be candidates for providing good outcomes. A complementary strategy 
is optimal for management of the risk factors for stroke. Therefore, choosing antihypertensive drugs for 
the prevention of stroke is important. Furthermore, various drugs other than thrombolytic drugs should 
be urgently initiated when stroke occurs. 
Currently, there is no evidence in clinical stroke research that ARBs are effective, even whether 
ARBs inhibit the HMGB1/RAGE axis. In patients who are currently taking the ARBs telmisartan, 
irbesartan, and candesartan, it is unclear whether the effect of inhibition of the HMGB1/RAGE axis 
directly contributes to stroke therapy. However, the extracellular release of HMGB1 appears to be 
common to the etiology and progression of multiple diseases leading to stroke, and may act in a 
multi-stage process in stroke. Therefore, the HMGB1/RAGE axis could be considered as a candidate 
molecular target for the treatment of stroke. Inhibition of the HMGB1/RAGE axis may prove to be a 
novel therapeutic strategy for treating stroke. Therefore, the inhibitory effect of ARBs on the 
HMGB1/RAGE axis may provide potential therapeutic effects in patients who require prevention and Int. J. Mol. Sci. 2013, 14  18912 
 
acute treatment of stroke (Figure 1). Telmisartan may be the most effective in terms of inhibition of 
RAGE via peroxisome proliferator-activated receptor-activation [5,149]. The choice of the optimal 
ARB for stroke therapy is difficult because there are few clinical studies in which ARBs have been 
directly compared regarding their neurovascular protective effects on stroke. Randomized, controlled 
clinical studies with large sample sizes should be performed. Studies using SHRSPs to compare the 
effects of all ARBs may be the most plausible means of comparison of the neurovascular protective 
effects of each ARB against stroke. New scientific strategies should continue to be explored to provide 
optimal care to stroke patients. 
Figure 1. Potential of telmisartan, irbesartan, and candesartan for inhibiting the 
HMGB1/RAGE axis in prevention and acute treatment of stroke. 
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